1. Translational Science in Cancer Health Disparities Research Peter Ujhazy, M.D., Ph.D. Program Director Translational Research Program Division of Cancer Treatment and Diagnosis National Cancer Institute E-mail:pu5s@nih.govpu5s@nih.gov http://trp.cancer.gov/ 2014 Professional Development Workshop June 23-24, 2014 Natcher Conference Center NIH Bethesda, MD

2. Continuum of Biomedical Research Translational research means different things to different people, but it seems important to almost everyone. The Meaning of Translational Research and Why It Matters Steven H. Woolf, MD, MPH JAMA. 2008;299(2):211-213.

3. Continuum of Biomedical Research Translational research means different things to different people, but it seems important to almost everyone. The Meaning of Translational Research and Why It Matters Steven H. Woolf, MD, MPH JAMA. 2008;299(2):211-213. Institute of Medicine’s Clinical Research Roundtable; Woolf, 2008; Kon, 2008

4. T1 = The transfer of new understandings of disease mechanisms gained in the laboratory into the development of new methods for diagnosis, therapy, and prevention and their first testing in humans T2 = The translation of results from clinical studies into everyday clinical practice and health decision making T3 = The task of discovering ways to move these findings into the daily care of patient(s) T4 = The challenge of moving scientific knowledge into the public sector and thereby changing people’s everyday lives Institute of Medicine’s Clinical Research Roundtable; Woolf, 2008; Kon, 2008 Definitions

5. T1 = The transfer of new understandings of disease mechanisms gained in the laboratory into the development of new methods for diagnosis, therapy, and prevention and their first testing in humans T2 = The translation of results from clinical studies into everyday clinical practice and health decision making T3 = The task of discovering ways to move these findings into the daily care of patient(s) T4 = The challenge of moving scientific knowledge into the public sector and thereby changing people’s everyday lives Institute of Medicine’s Clinical Research Roundtable; Woolf, 2008; Kon, 2008 Definitions

6. Translational Research Program (TRP)TRP Division of Cancer Treatment and Diagnosis (DCTD)DCTD National Cancer Institute (NCI)NCI National Institutes of Health (NIH)NIH 9609 Medical Center Drive, Room 3W110, MSC 9726 Rockville, MD 20850-9726 Tel: 240-276-5730; Fax: 240-276-7881 Specialized Programs of Research Excellence (SPORE) SPORE SPORE Web-site: http://trp.cancer.govhttp://trp.cancer.gov

7. Translational Research in the SPORE Program Translational research uses knowledge of human biology to develop and test the feasibility of cancer-relevant interventions* in humans AND/OR determines the biological basis for observations made in individuals with cancer or in populations at risk for cancer * The term “interventions” is used in its broadest sense to include molecular assays, imaging techniques, drugs, biological agents, and/or other methodologies applicable to the prevention, early detection, diagnosis, prognosis, and/or treatment of cancer.

8. SPORE Requirements P50 Specialized Center Grant  Minimum of four research projects including the “required project”  All projects must be translational  Administrative Core  Scientific Collaboration (SC)  Shared Resources Cores:  Biospecimen/pathology: required  Stats, clinical, animal, etc.: optional  Developmental Research Program (DRP)  Career Development Program (CDP)  External Advisory Board Members  Commitment to attend and participate in NCI sponsored meetings/workshops  Minimum Time Commitment:  SPORE director(s): > 2.4 calendar months  Project co-leader: > 0.6 calendar months  Core director: > 0.6 calendar months  DRP/CDP director: > 0.3 calendar months

9. January 2014, Vol. 21, No. 1

11. Overall survival of non–small-cell lung cancer patients by time period (Moffitt) Schabath et al, 2014

12. Overall survival of NSCLC patients by time period and stage (Moffitt) Stage I-II Stage III Stage IV Schabath et al, 2014

13. Multivariable Cox Proportional Hazard Models for 5 Time Periods Schabath et al, 2014

15. Survival among the subset of 86 HIV-infected HNC cases with survival data, CD4 at diagnosis, HPV composite status, tumor site, and cancer stage D’Souza et al, 2014

16. Comparison of HIV-HNC with US-HNC general population D’Souza et al, 2014

17. PatientsHIV-HNCUS-HNC Male91%68% Median Age50 years62 years Nonwhite49%18% Current smokers61%18% Median survival63 months61 months Comparison of HIV-HNC with US-HNC general population

18. Conclusion: Risk factors for the development of HNC in patients with HIV infection are similar to the general population, including both HPV-related and tobacco/alcohol-related HNC.